Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fazpilodemab
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Fazpilodemab is a humanized, agonistic bispecific monoclonal antibody that targets fibroblast growth factor receptor 1c (FGFR1c) and Klotho beta (KLB). It was developed for the treatment of non-alcoholic steatohepatitis (NASH), with additional investigation in type 2 diabetes mellitus and non-alcoholic fatty liver disease. Fazpilodemab acts as an agonist at FGFR1c/KLB complexes, aiming to reduce liver fat and improve metabolic parameters. The drug was developed by Genentech, a subsidiary of Roche. Clinical development reached phase II for NASH but was terminated due to strategic business reasons[1][3][4][5].
- Other names
- anti-FGFR1/KLB bispecific antibodyFGF21 mimetic antibodyFGF-21 mimetic antibodyFGF 21 mimetic antibody
02
Targets
KLB (Beta-Klotho)FGFR-KLB complex (Fibroblast growth factor receptor 1c / beta-Klotho complex)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on fazpilodemab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fazpilodemab.